A 63-year-old man was evaluated for a lifelong history of bleeding commencing with frequent epistaxis as a child; all previous routine coagulation parameters were within the normal range. The patient's hemorrhagic disorder is characterized predominantly by delayed bleeding at surgical sites. In the resting state, there was no clinical or laboratory evidence of excessive fibrin(0gen)olysis. Bleeding was not caused by disseminated intravascular coagulation, factor Xlll deficiency, a2-antiplasmin deficiency, or dysfibrinogenemia. It was found that the patient was deficient in plasma PAI-1 antigen and activity but with approximately half normal antigen and normal activity of platelet PAI-1. The low ASCULAR FIBRINOLYSIS is a complex and critical V process for controlling hemostasis and thrombosis. It is precisely regulated and is initiated by the release of active tissue plasminogen activator (t-PA) from endothelial cells. t-PA activity is very low in normal and the majority of t-PA is complexed with type 1 plasminogen activator inhibitor (PAI-l).3 PAI-1 is a relatively unstable molecule with two different conformational forms-active and latent!.5 Binding of PAL I to vitronectin stabilizes the active conformation?,' PAL1 is in human plasma, platelets, and basement At present, the origin of plasma PAI-1 is not known, but it is most likely that endothelial cells and/or liver are responsible for plasma PAI-1 prod~ction.~ Platelet PAI-1 is present in a granules.'
PAI-1 in the fibrinolytic system, suggesting that it is the primary regulatory element in this system!,' It inhibits both t-PA and urokinase activity by forming a stoichiometric complex with either activator. Computer-simulated kinetic models for the active t-PA levels in plasma predicted that the level of active PAI-1 in the blood is an important regulator of the concentration, half-life, and circadian variation of active t-PA."
Several pathophysiologic problems are reported in relation to abnormal concentrations of plasma PAI-1. Increased PAI-1 activity in blood appears to be associated with certain thromboembolic diseases, such as myocardial infarction,'l,12 deep vein thrombo~is,'~*'~ and postoperative thrombosis in patients undergoing elective hip surgery. 15 However, direct evidence to support the conclusion that elevated PAI-I activity in blood is a major cause of thrombosis remains to be verified because a IO-fold increase in plasma PAL1 occurs during pregnancy and is not strongly associated with thromboembolic diseases. 16 There may be a convincing, if limited, correlation between decreased PAI-I activity and a hyperfibrinolytic bleeding tendency. Hyperfibrinolytic bleeding is characterized by normal platelet and coagulation activities. Delayed bleeding occurs because a normal hemostatic plug is formed, but it is later more susceptible to breakdown owing to increased fibrinolytic activity. Presently, there are five dissimilar cases reported relating decreased PAI-1 activity to hyperfibrinolytic bleeding. DiCval et a1 reported a case of a lifelong delayed bleeding disorder associated with a quantitative deficiency of concentration of plasma PAL1 was insufficient to neutralize circulating t-PA, resulting in high t-PA activity with normal antigen and causing the hyperfibrinolytic activity observed. Studies on seven family members of the proband indicated autosomal inheritance of plasma PAL1 deficiency. Studies on this patient emphasize a clear correlation between decreased plasma PAL1 activity and hyperfibrinolytic bleeding and also emphasize the unique role of plasma PAL1 in the balance between the coagulation and fibrinolytic mechanisms.
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PAI-I in their patient's plasma but with a normal level of PAL1 in platelets"; Francis et all8 described a patient with amyloidosis who had severe bleeding and produced autoantibodies against PAI-1. A patient with low PAL 1 activity and normal PAI-1 antigen was reported by Schleef et all9; and a postoperative bleeding case associated with an excess of t-PA activity and low PAI-1 activity was reported by Stankiewicz et aLZ0 Fay et alZ1 recently reported a case of deficient PAL1 in plasma and platelets that was explained by a molecular defect in the PAI-l gene.
In this report, we present a patient with low plasma levels of PAL1 antigen and activity but with functional platelet PAL 1, which was associated with a lifelong delayed bleeding disorder. We also report plasma PAI-1, t-PA activity, and antigen levels in the patient's family members.
MATERIALS AND METHODS
After the patient had rested for 15 minutes, blood was collected into Vacutainer tubes (Becton Dickinson, Rutherford, NJ) containing sodium citrate. Blood was centrifuged (2, 00Og , 30 minutes) to prepare platelet free plasma for PAI-I antigen and activity and t-PA antigen measurements. For t-PA activity measurement, blood was immediately acidified and centrifuged (2, 0OOg , 20 minutes) to prepare acidified plasma, followed by activity determinations (COA-SET t-PA; Kabi Diagnostica, Frankline, OH).
Serum was prepared from blood, collected into Vacutainer tubes without anticoagulant. It was incubated at room temperature for 30 minutes, and the clot was removed by centrifugation (2,OOOg 20 minutes). Serum was used to measure PAI-I activity and antigen secreted from the platelets. Patient's and normal fibrinogens were prepared, and fibrinopeptide release was determined on a C,s-high-pressure liquid chromatograph (HPLC) as previously described?' Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by the method of I~iemmli.'~ Fibrin degradation products were measured on serum by latex agglutination (Thrombo-Wellcotest; Wellcome, Triangle Park, NC), and D-dimer was also measured by latex agglutination (D-dimer test; Diagnostica Stago, AsniZres, France).
t-PA activity (COA-SET t-PA, Kabi Diagnostica) and PAI-I activity (COA TEST PAI; Kabi Diagnostica) were measured with chromogenic assays. PAL 1 activity is expressed as arbitrary units (AU). One AU of PAI-I is the amount that inhibits I U of t-PA during a IO-minute incubation of samples with standard t-PA under experimental conditions (COA TEST PAI; Kabi Diagnostica). t-PA antigen was measured as total t-PA antigen by an enzyme immunoassay, using a monoclonal antibody that measures free t-PA and t-PA-PAL1 complex (Corvas, San Diego, CA). This assay is reactive to both one-and two-chain t-PA. PAI-I antigen was also measured by an enzyme immunoassay, either by TintElize PAL1 (Biopool, Hamilton, Ontario, Canada) or by Imubind PAL1 (American Diagnostica, Greenwich, 0). In these assays, active, latent and complexed forms of PAI-I had the same response., according to the manufacturers; so, these. assays measured total PAI-I antigen.
Fibrinogen assays.
t-PA and PAI-1 measurements.
RESULTS

Case report.
The patient is a 63-year-old man with a history of bleeding commencing with frequent episodes of epistaxis as a child. No complications were reported at birth. At age 18, he bled for I month beginning the day after dental extractions and for 1 week beginning the day after tonsillectomy. Three inguinal hernia operations (ages 2 1 to 26) were characterized by normal hemostasis on the day of surgery, followed by hematoma formation and bleeding from the incision for up to 1 month. At age 52, the patient had hematuria for 1 month after a transurethral prostate resection. At age 57, inguinal surgery was again complicated by delayed bleeding, which promptly stopped when he was administered fresh frozen plasma. The patient has frequent and significant bruising but no spontaneous hemarthrosis or hematomas. He has had numerous hemostatic evaluations and was once told that he had factor V deficiency. His family history is significant in that both of his brothers reported some excessive delayed bleeding after dental extractions. His physical examination was normal except for a Marie-Charot-Tooth neuropathy. Clinical test results are summarized in Table 1 . All the coagulation parameters appeared to be within the normal range except the thrombin time and the reptilase time, which were in the upper limit of normal range or slightly prolonged. This originally led us to investigate the possibility of abnormal fibrinogen. Also, the von Willebrand factor (vWF) antigen and cofactor activity were just below the normal range.
Patient jbrinogen andjibrinopeptide. Patient fibrinogen was purified in the normal manner from fresh frozen plasma by passage over gelatin-Sepharose and lysine-Sepharose affinity columns followed by repeated (NH4)2S04 precipitation." The SDS-PAGE result is shown in Fig 1 . Surprisingly, Bleeding recurred 16 hours later.
the molecular weight of the patient's fibrinogen was lower (-200 Kd) than the control fibrinogen (340 Kd) prepared at the same time. Total fibrinopeptides released from the patient's fibrinogen compared with the control fibrinogen are shown in Fig 2 (A and B) . Only about 20% of fibrinopeptide B was released compared with fibrinopeptide A in the patient's fibrinogen, whereas in the control fibrinogen, both fibrinopeptides A and B were completely released. It appeared that the fibrinogen isolated from the patient was a degradation product (mostly fragment X) of native fibrinogen (Fig 1) . However, a fast and crude preparation of patient's fibrinogen by 25% (NH4)2S04 precipitation only, twice in I hour, resulted in intact fibrinogen, with complete fibrinopeptide A and B release after thrombin treatment (Fig 2C) . In this experiment, the fibrinogen was purified and analyzed approximately 2 hours after the blood was drawn. This finding indicated that the circulating fibrinogen was normal but that this patient had hyperfibrinolytic activity in his plasma. Presumably, the fibrinolytic system was activated in this case by blood collection or in the initial steps of purification. To identify the cause of this hyperfibrinolytic activity in the patient, we measured plasma levels of t-PA and PAI-l. Because t-PA and PAI-I are diurnally fluctuating proteins,24 blood samples were drawn around 2:OO PM, along with 20 healthy normal controls, 20 to 67 years of age. The average of four determinations of the activities of both t-PA and PAL 1 and the antigen levels of t-PA and PAL1 are shown in Table 2 .
t-PA activity in the patient's plasma (1.9 -+ 0.1 U/mL) was greater than that of the control (0.9 f 0.3 U/mL), whereas the t-PA antigen level in the patient's plasma (5.2 ? 0.2) was the same as the control group (4.9 k 2.0). PAI-1 activity in Plasma t-PA and PAI-I activity and antigen level.
For the patient's plasma (0.8 f 0.8 AU/mL) was essentially unmeasurable compared with the control (6.0 f 3.8 AU/mL). The PAI-I antigen was also very low (1.9 f 1. I ) compared with the control (26 f 14) . Therefore, it was concluded that the hyperfibrinolytic bleeding disorder in our patient was associated with a significantly low level or an absolute deficiency of plasma PAL I activity and antigen. As a result ofthis, most of the plasma &PA circulated as a free form with high activity.
The circulating free t-PA in the patient's plasma was calculated to be -4.5 ng/mL, with the specific activity of 425,OOO IU/m& given for the International t-PA standard (86/670). The free 1-PA in normal controls was calculated to be -2 ng/mL. Although we cannot rule out the possibility that this patient also had mild von Willebrand disease (type I), which would contribute to his bleeding syndrome, the very low PAI-I activity and antigen in his plasma and the high circulating t-PA activity were principally responsible for the bleeding syndrome in this patient.
Because there was the possibility of not only a deficiency of plasma PAI-I but also a deficiency of platelet PAI-I, we measured the activity and the antigen level in the patient's serum ( Table 3) . In normal, healthy people, the concentration of PAL1 antigen Serum PAI-I activity and antigen level. 2359 in platelets is reported to be much higher (270.3 f 7 I .9 ng/ mL) than in plasma (21.0 f 7.2 ng/mL)? but platelet PAI-1 exists primarily in an inactive, latent form, with only 3% to 4% being active compared with the plasma PAL I .9. 25 As would be expected, antigen levels in the patient's serum ( 1 I 1 f 16 ng/mL) and the control group (229 f 25 ng/mL) were considerably higher than in plasma. PAI-I antigen in the patient's platelets was approximately half (with a normal platelet count, 204,OOO/pL) compared with the control, but it appeared to be released normally on platelet aggregation. The PAL 1 activity of patient's serum (6.7 f I .5) and control ( I I .4 f 3.0) were significantly higher than the values of plasma ( Table 3 For personal use only. on October 25, 2017 . by guest www.bloodjournal.org From serum and plasma was similar to that ofcontrols, -6 AU/ mL. This finding indicated that PAL1 in patient's platelets was released normally on platelet aggregation, although the concentration in platelets Was approximately half of the Control.
plasma. We also measured the probands six available family members' plasma t-PA and PAI-1 activity and antigen levels on two OCCaSiOnS. Blood Was drawn in the afternoon after a 15-minUte interval Of rest, and measurements Were done immediately for PAI-1 and t-PA activity. PAI-1 and t-PA antigen were measured the next day 0x1 Plasma kept at 4°C. The test results along with the pedigree of the Patient's family are shown in Fig 3. The proband's three siblings had somewhat low levels Of PAI-1 activity (below 1 SD from the mean). His sister probably would have no detectable PAI-1 activity with repeated testing. At the Same time, all siblings had t-PA activity >2 SD above the mean. The siblings, like the proband, had normal t-PA antigen levels.
functional activity of PAI-1.I9 Both plasma and platelet PAI-1 had low activity with normal antigen level and diminished complex formation with t-PA resulting in hyperfibrinolysis. The exact defect in this patient's pAI-1 molecule was not characterized. However, it was suggested that an abnormality t-PA and PM-1 in the Patient's family ~~~b e r s '
could be due to alternative processing of PAL1 mRNA or to a defect in the 12.2-kb PAI-I gene.
Francis et all8 reported a patient with amyloidosis with delayed bleeding and accelerated fibrinolysis in whom there were neutralizing antibodies to PAI-1 and a noma] t-PA antigen level but high t-PA activity, In 1983, Booth et a] reported a case of a lifelong hemorrhagic disorder due to excess plasminogen activator, but the role of pA1-1 in this case was not investigated.31
Our patient clearly shows that a quantitative deficiency of plasma PAL1 activity and antigen levels is associated with a lifelong delayed bleeding disorder. The decrease in plasma pAI-1 results in an elevation of the free t-pA activity in plasma, which in this patient was calculated to be -5 ng/ mL. The total 1-PA concentration in this patient's plasma was determined to be 8 ng/mL, which is comparable with the calculated free 1-PA concentration. Thus, most of the plasma t-PA circulated as a free form with high activity causing a hyperfibrinolytic state in the plasma. Because 93% of the total PAI-I antigen in blood is reported to be present in platelets,' the trace amount of PAL1 sometimes detected in the patient's plasma could have been derived from his platelets or could be due to the vagaries of the assays. His serum had significant levels of PAI-1 antigen; approximately half that compared with the control.
DISCUSSION
Delayed bleeding disorders can be associated with abnormal fibrinolysis. They also have been associated with deficiencies of several proteins involved in the regulation of fibrinolysis, including antipla plasm in,^^.^^ factor XIII,28*29 and PAI-I.17,'9 Factor XIIIa regulates fibrinolysis in two ways: by introducing covalent cross-links into fibrin and by cross-linking a,-antiplasmin to fibrin.30 These cross-linking reactions render the fibrin clot more resistant to degradation by plasmin. Factor XI11 deficiency is characterized by delayed bleeding because a non-cross-linked clot is formed and is more readily lysed by plasmin. a2-Antiplasmin is the primary inhibitor of plasmin activity in blood. a2-Antiplasmin deficiency is also characterized by delayed bleeding; in this case because a normal clot forms, but it then lyses readily because there is no inhibitor to abate plasmin activity.
Decreased PAI-I activity may be caused by quantitative defects, qualitative defects, or antibodies against PAL 1. There are two documented cases of a quantitative PAL1 deficiency, and both were associated with a lifelong hemorrhagic disorder.17 '21 In one case, both PAL 1 antigen and activity in the patient's plasma were below the sensitivity of the assays, whereas platelet PAI-I activity and antigen were normal. For personal use only. on October 25, 2017 . by guest www.bloodjournal.org From
The inheritance of congenital PAI-1 deficiency is not clear from the literature or from this case. The proband has a small family living in this country. His siblings seemed to have low PAL1 activity and high t-PA activity with normal antigen. This would point to this being an inherited characteristic; but at present, these assays cannot define heterozygotes with certainty.
The observation that this patient had a quantitative deficiency of plasma PAI-1 but normal functional platelet PAI-1 suggests the importance of compartmentalization of PAI-1. Because platelets have approximately 10 times more PAI-1 antigen than the circulating plasma, and because platelet PAL1 is released after platelet activation, it is not obvious why a deficiency in the plasma compartment only could result in serious bleeding. Simpson et a132 reported that the plasma and platelet pools of PAL1 vary independently in various disease states, and the two pools of PAL1 do not seem to mix. It may be that plasma PAL1 is responsible for immediate complex formation with circulating t-PA. The primary function of the platelet compartment of PAL1 is debated33 because PAI-1 is released from platelets mostly in an inactive form. It could participate in localized, regulatory functions of blood coagulation and fibrinolysis in plateletmatrix interactions and in the protection of the matrix against prote~lysis.~~ The role of PAI-1 released from activated platelets is thought to be a major determinant for clot-lysis resistance3' and to be associated with thrombolysis resist a n~e .~~.~~ It may protect the blood clot against premature lysis during coag~lation,~ but it is not available at later times when delayed bleeding might occur. However, Kunitada et a133 recently showed that although platelets impair clot lysis by t-PA in vitro, this is not owing to inactivation by PAL1 but to clot retraction and decreased binding of the plasminogen activator. One can speculate that the precise local concentrations of PAI-1 and the dynamic time course are important in controlling hemorrhage. This patient emphasizes the importance of the role of plasma PAI-I in some hyperfibrinolytic bleeding disorders.
